Related Experiment Videos
IAP family proteins delay motoneuron cell death in vivo
D Perrelet1, A Ferri, A E MacKenzie
1Division Clinical Neuromuscular Research. & Department of APSIC, Faculty of Medicine, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. Daniel.Perrelet@medecine.unige.ch
Abstract:
Neuronal apoptosis inhibitory protein (NAIP), and human inhibitors of apoptosis 1 and 2 (HIAP1 and HIAP2) are three members of the mammalian family of antiapoptosis proteins called 'inhibitors of apoptosis' (IAP). These molecules can prevent apoptosis in vitro and the over-expression of NAIP can decrease ischemic damage in the hippocampus. The goal of our experiments was to determine whether administration of NAIP, HIAP1 and HAIP2 could rescue motoneurons following axotomy of a peripheral nerve. In young rats, an adenoviral gene transfer technique was used to deliver and express these proteins in motoneurons; a fluorescent tracer was simultaneously added as a means for quantitatively assessing the rescue of fluorescently labelled motoneurons in serial sections of the lumbar spinal cord. Control experiments using adenoviral vectors (adv) expressing the lacZ gene showed that 14% of the sciatic motoneuron pool could be transfected indicating the existence of a subpopulation of spinal motoneurons susceptible to this class of viral vectors. The administration of an adv-NAIP, adv-HIAP1 and adv-HIAP2 rescued 30-40% of motoneurons at one week after sciatic axotomy. The efficiency of these proteins was similar to that of two neurotrophic factors, ciliary neurotrophic factor and brain-derived neurotrophic factor, administrated by the same viral technique. The effect of the IAP proteins on motoneuron survival decreased with time but was still present after 4 weeks postaxotomy; the duration of the response was dependent upon the viral titre. These experiments demonstrate that IAP family proteins can prevent motoneuron cell death in vivo and may offer a new therapeutic approach for motoneuron diseases.
Insights
Inhibitors of apoptosis (IAP) proteins, including neuronal apoptosis inhibitory protein (NAIP), human inhibitors of apoptosis 1 (HIAP1), and 2 (HIAP2), effectively rescued motoneurons after peripheral nerve injury in rats. This suggests IAPs as a potential therapy for motoneuron diseases.
Area of Science:
- Neuroscience
- Cell Biology
- Molecular Medicine
Background:
- Neuronal apoptosis inhibitory protein (NAIP) and human inhibitors of apoptosis (HIAP) 1 and 2 are anti-apoptotic proteins.
- In vitro studies show these proteins prevent apoptosis, and NAIP overexpression reduces ischemic damage.
- Motoneuron survival after injury is a critical area for therapeutic development.
Purpose of the Study:
- To investigate the efficacy of NAIP, HIAP1, and HIAP2 in rescuing motoneurons following peripheral nerve axotomy in vivo.
- To evaluate the potential of IAP proteins as a therapeutic strategy for motoneuron diseases.
Main Methods:
- Adenoviral gene transfer was used to deliver NAIP, HIAP1, and HIAP2 into rat motoneurons.
- A fluorescent tracer quantified surviving motoneurons in the lumbar spinal cord.
- Control experiments utilized adenoviral vectors expressing lacZ to assess transfection efficiency.
Main Results:
- Adenoviral vectors successfully transfected approximately 14% of the sciatic motoneuron pool.
- Administration of adv-NAIP, adv-HIAP1, and adv-HIAP2 rescued 30-40% of motoneurons one week post-axotomy.
- The neuroprotective effect of IAP proteins persisted for at least 4 weeks, with duration dependent on viral titre.
Conclusions:
- Inhibitors of apoptosis (IAP) family proteins demonstrate in vivo efficacy in preventing motoneuron cell death after nerve injury.
- IAP proteins show comparable neuroprotective potential to established neurotrophic factors like ciliary neurotrophic factor and brain-derived neurotrophic factor.
- These findings highlight IAP proteins as a promising therapeutic avenue for treating motoneuron diseases.